Read more
Provides an update on the status of biosimilars and a perspective for the next decade. How biosimilars are developed in the future will include many AI-based features to establish structural similarity that will prevent the need for most other testing, including detailed analytical assessment and clinical pharmacology testing.
List of contents
Preface
Chapter 1 All About Biosimilars
1. Introduction
2. Approvals
3. Future Candidates
4. Approval Guidelines
5. Waivers
6. Appendix: Terminology
7. Appendix 2: Therapeutic Proteins approved by the FDA: potential biosimilar candidates.
8. Bibliography
Chapter 2 Product Type and Selection Strategies
1. Background
2. Exclusivity
3. Formulation
4. Route of Administration
5. Reference Product
Chapter 3 Development Master Plan
1. Introduction
2. Creating a Plan
3. Intellectual Property
4. Expression System
5. Release Specification
6. Nonclinical Testing
7. Clinical Pharmacology Assessment
8. Clinical Immunogenicity Assessment
9. Clinical Efficacy Assessment
10. Extrapolation of Clinical Data Across Indications
11. Interchangeability and Substitution
Chapter 4 Optimization of Cost of Goods
1. Background
2. Creation of Cell Lines
3. Media
4. Containers and Mixing Systems
5. Working downstream
6. Regulatory
7. Ongoing Production
8. Continuous Manufacturing
Chapter 5 Strategic Understanding for Biosimilars Future
1. Introduction
2. The Role of the US Congress
3. The Role of the FDA
4. The Role of Developers
5. The Role of the Associations
6. Conclusions
Chapter 6 Repurposing Biosimilars
1. Introduction
2. Understanding Therapeutic Proteins
3. Reinvention Scope
4. Intellectual Property
5. Artificial Intelligence (AI) and Machine Learning (ML)
6. Structure Prediction
7. Target identification
8. Molecular Docking
9. Drug Conjugates
10. Regulatory Perspective
11. Conclusions
12. References
About the author
Sarfaraz K Niazi, Ph.D., is an Adjunct Professor at the University of Illinois. He has authored 60+ major books, 100+ research papers, and 100+ patents, mainly in bioprocessing. He has hands-on experience establishing biopharmaceutical projects, from concept to market, including setting up the first biosimilar company in the US and leading to several FDA approvals. He serves as an advisor to several regulatory agencies, including the FDA.
Summary
Provides an update on the status of biosimilars and a perspective for the next decade. How biosimilars are developed in the future will include many AI-based features to establish structural similarity that will prevent the need for most other testing, including detailed analytical assessment and clinical pharmacology testing.
